ATS Corporation heads into its fiscal second-quarter report with a striking disconnect. Management spent its last call laying out a more detailed and more confident path to fatter margins, adding a radiopharmaceutical opportunity it described as worth more than $100 million per isotope facility. The market responded by marking the shares down nearly 23% while the S&P 500 barely moved. That gap is the story. Either investors are pricing in a revenue air pocket that the margin plan cannot offset, or the stock has run ahead of the fundamentals on the downside.
The Street is bracing for a genuine contraction. Consensus calls for earnings of $0.22 a share on revenue of roughly $485.4 million, which would mean a 33% drop in profit and an 8% decline in sales from a year ago, when ATS earned $0.33 on $529 million. It would also mark a step down from last quarter's $0.25 on $501.1 million. The Earnings Whisper sits at $0.24, a little above consensus, suggesting the more engaged crowd sees modest room for an upside surprise but not a dramatically different quarter.
Some of the slide is self-inflicted and was well telegraphed. Management cut its fiscal 2027 outlook to modest growth from the high single-digit organic pace it had reaffirmed earlier, citing about $50 million of transportation revenue it is deliberately walking away from and a life sciences backlog that has normalized after the GLP-1 auto-injector surge. A year-over-year revenue decline of the size consensus implies sits uncomfortably beside a full-year modest growth framing, so this report needs to show either that the second half will carry the load or that the outlook is slipping. Any revision to the annual view will matter more than the quarterly print itself.
The margin bridge is where the narrative will be tested. ATS described roughly 500 basis points of expansion from a 10.6% fiscal 2026 base toward a 15% EBIT target, with about half coming from its fixed-cost transformation program and the rest from aftermarket, services and its ABM business system. It went further, hinting that 15% could become a floor rather than a ceiling, and set a nearer-term goal of exiting fiscal 2027 with margins 50 to 75 basis points higher. On revenue that is shrinking, visible progress on adjusted margins would be the strongest validation available. Flat or lower margins, especially if restructuring charges keep running above the $10 million to $20 million management flagged for the year, would undercut the central premise that pruning the portfolio makes ATS a better business.
Orders are the other swing factor. Bookings fell 18% year over year in the fiscal fourth quarter and the trailing book-to-bill ratio slipped below 1.0, down from 1.12 two quarters earlier. A rebound toward or above parity, supported by nuclear and energy backlog that has been growing at double-digit rates and early radiopharma orders, would suggest the revenue trough is near. Another sub-1.0 reading would feed the bear case that life sciences softness runs deeper than portfolio cleanup. Investors will also want an update on the radiopharma partnership and the FlexLine sterile production platform, plus how management intends to use balance-sheet capacity now that leverage has fallen to 2.8 times EBITDA.
Sentiment has cooled from mildly bullish heading into last quarter to slightly bearish now, and the chart reflects it. At $18.95, the stock sits far below its 200-day moving average of $26.85 and near the bottom of its post-earnings range of $17.15 to $24.57, a band that lies entirely beneath last quarter's lows. Expectations are clearly subdued. The question this report must answer is whether ATS can show margins rising and orders stabilizing while sales shrink. If it can, the selloff looks overdone; if not, the margin story risks being dismissed as a promise rather than a plan.